Merck KGaA on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by cost-cutting measures and ...

The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

Merck & Co was founded in 1970 and operates in Rahway, United States. The company engages in the sector 'Pharmaceuticals, Medicinal Chemical & Botanical Products' (ISIC: 2100). This industry ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

M Chemical, a chemical subsidiary of Merck Korea, has been fully integrated into the German life science and electronics company's semiconductor entity. Starting from Monday, M Chemical is under ...

Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for ...

The Merck Index Online is an encyclopaedic database of chemical substances – an evolution of the printed reference work The Merck Index. While the content has a focus on chemicals and biologicals of ...

They will present their research at a Women Chemists Committee (WCC)/Merck half-day symposium and be recognized ... Medicinal, Analytical, Chemical Biology, Computational or Structural Chemistry, and ...

Merck KGaA's shares jumped after the German ... The life-sciences and chemicals group lifted its mid-term outlook for its electronics business, which supplies materials to the chip and display ...

Anyone crafting a bull case for the pharmaceutical giant Merck (NYSE: MRK) should include Keytruda as the company's best asset. The cancer drug has been Merck's top-selling medicine and its ...

(RTTNews) - Merck & Co., Inc. (MRK) announced the positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the company's investigational prophylactic monoclonal ...